These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37675624)

  • 1. Tryptamine: A privileged scaffold for the management of Alzheimer's disease.
    Singh YP; Kumar H
    Drug Dev Res; 2023 Dec; 84(8):1578-1594. PubMed ID: 37675624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbamate as a potential anti-Alzheimer's pharmacophore: A review.
    Singh YP; Kumar N; Chauhan BS; Garg P
    Drug Dev Res; 2023 Dec; 84(8):1624-1651. PubMed ID: 37694498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer's disease.
    Zhang F; Zhong RJ; Cheng C; Li S; Le WD
    Acta Pharmacol Sin; 2021 Sep; 42(9):1382-1389. PubMed ID: 33268824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Developments in Tacrine-based Hybrids as a Therapeutic Option for Alzheimer's Disease.
    Yamali C; Donmez S
    Mini Rev Med Chem; 2023; 23(7):869-880. PubMed ID: 36464869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
    Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
    Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease.
    Singh YP; Rai H; Singh G; Singh GK; Mishra S; Kumar S; Srikrishna S; Modi G
    Eur J Med Chem; 2021 Apr; 215():113278. PubMed ID: 33662757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donepezil Derivatives Targeting Amyloid-β Cascade in Alzheimer's Disease.
    Mezeiova E; Chalupova K; Nepovimova E; Gorecki L; Prchal L; Malinak D; Kuca K; Soukup O; Korabecny J
    Curr Alzheimer Res; 2019; 16(9):772-800. PubMed ID: 30819078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the rationale for new treatment strategies in Alzheimer's disease?
    Rogawski MA
    CNS Spectr; 2004 Jul; 9(7 Suppl 5):6-12. PubMed ID: 15241294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
    Sharma P; Tripathi MK; Shrivastava SK
    Methods Mol Biol; 2020; 2089():257-286. PubMed ID: 31773661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive review of multi-target directed ligands in the treatment of Alzheimer's disease.
    Pathak C; Kabra UD
    Bioorg Chem; 2024 Mar; 144():107152. PubMed ID: 38290187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.
    Morató X; Pytel V; Jofresa S; Ruiz A; Boada M
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors.
    Przybyłowska M; Dzierzbicka K; Kowalski S; Chmielewska K; Inkielewicz-Stepniak I
    Curr Neuropharmacol; 2021; 19(8):1323-1344. PubMed ID: 33342413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease.
    Li Q; He S; Chen Y; Feng F; Qu W; Sun H
    Eur J Med Chem; 2018 Oct; 158():463-477. PubMed ID: 30243151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease.
    Saeedi M; Mehranfar F
    Recent Pat Biotechnol; 2022; 16(2):102-121. PubMed ID: 35236274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TV 3326 for Alzheimer's dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer's-like neuropathology.
    Uddin MS; Kabir MT; Rahman MM; Mathew B; Shah MA; Ashraf GM
    J Pharm Pharmacol; 2020 Aug; 72(8):1001-1012. PubMed ID: 32149402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model.
    Ju Y; Tam KY
    Neuropharmacology; 2020 Dec; 181():108354. PubMed ID: 33035533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early administration of galantamine from preplaque phase suppresses oxidative stress and improves cognitive behavior in APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Saito T; Hisahara S; Iwahara N; Emoto MC; Yokokawa K; Suzuki H; Manabe T; Matsumura A; Suzuki S; Matsushita T; Kawamata J; Sato-Akaba H; Fujii HG; Shimohama S
    Free Radic Biol Med; 2019 Dec; 145():20-32. PubMed ID: 31536772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinesterase inhibitors for Alzheimer's disease.
    Birks J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of oxidative stress and other pathologies in Alzheimer's disease.
    Simunkova M; Alwasel SH; Alhazza IM; Jomova K; Kollar V; Rusko M; Valko M
    Arch Toxicol; 2019 Sep; 93(9):2491-2513. PubMed ID: 31440798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.